关于血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂在2019冠状病毒病（COVID-19）中应用的共识声明。
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
作者信息
Talreja Hari, Tan Jasmine, Dawes Matt, Supershad Sharen, Rabindranath Kannaiyan, Fisher James, Valappil Sajed, van der Merwe Veronica, Wong Lisa, van der Merwe Walter, Paton Julian
机构信息
Consultant Nephrologist, Counties Manukau DHB.
Consultant Nephrologist, Waitematā DHB.
出版信息
N Z Med J. 2020 Apr 3;133(1512):85-87.
There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.
一直有很多猜测认为，正在接受血管紧张素转换酶（ACE）抑制剂或血管紧张素受体阻滞剂（ARB）治疗的2019冠状病毒病（COVID-19）患者可能出现不良结局的风险会增加。我们回顾了现有证据，并未发现情况属实。我们建议正在服用此类药物的患者应继续用药，除非有临床指征表明需要停药。
Zotero 插件